What Is the Mechanism of Action of DPP-4 Inhibitors?

DPP-4 inhibitors work by blocking an enzyme called dipeptidyl peptidase-4, which normally breaks down gut hormones that help control blood sugar after meals. By keeping those hormones active for longer, these drugs boost insulin release and dial back glucagon secretion, but only when blood sugar is elevated. That glucose-dependent action is a big part of why they carry a low risk of hypoglycemia compared with older diabetes medications. The story goes deeper than that simple summary, though, because the enzyme they target does far more than chop up a couple of hormones.

The Enzyme They Target

DPP-4 is a protein that exists in two forms: one anchored to cell surfaces across many tissues (kidneys, gut lining, immune cells, blood vessels) and one circulating freely in the blood. Both forms are enzymatically active, snipping peptides that have an alanine or proline in the second position of their amino acid chain.¹ That cleavage either inactivates the target peptide or, in some cases, creates a new fragment with its own biological activity.² The enzyme’s substrate list is long. GLP-1 and GIP get the most attention in diabetes treatment, but DPP-4 also cleaves neuropeptides, chemokines, and other signaling molecules, which helps explain why blocking it can have effects well beyond blood sugar.

How Blocking DPP-4 Lowers Blood Sugar

When you eat, your gut releases two incretin hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones travel through the bloodstream to the pancreas, where they amplify the insulin response to rising glucose. The catch is that DPP-4 chews them up within minutes. A DPP-4 inhibitor slows that breakdown, extending the time these hormones stay intact and active after a meal.³

The downstream effects on the pancreas are two-fold. Beta cells, which produce insulin, get a stronger signal to release it when blood sugar is high. Alpha cells, which produce glucagon (a hormone that raises blood sugar), get a signal to dial back. This dual action pushes blood sugar down more effectively than targeting either cell type alone. The effect is tied to actual glucose levels: when blood sugar is normal or low, the incretin signal fades, so insulin secretion drops and glucagon is allowed to rise again. That built-in safety switch is why DPP-4 inhibitors rarely cause dangerously low blood sugar on their own.⁴

Direct Effects on Pancreatic Beta Cells

The incretin-boosting story is well-established, but there is growing evidence that DPP-4 inhibitors also affect beta cells more directly. The enzyme itself is present on the surface of human beta cells and alpha cells. When researchers inhibited DPP-4 directly on isolated human islets in the lab, the beta cells secreted more insulin in response to glucose, showed less programmed cell death, and had healthier internal structure, even in islets taken from people with type 2 diabetes.⁵ That suggests DPP-4 inhibition has local, on-the-spot benefits for the insulin-producing cells themselves, not just indirect effects through circulating hormones.

In animal models of diabetes, DPP-4 inhibitor treatment has led to increased beta cell mass, higher insulin content in the pancreas, and improved glucose sensing over weeks and months of treatment.⁶ In one mouse study, vildagliptin treatment for six weeks roughly doubled circulating active GLP-1 levels and significantly reduced beta cell death, as measured by both cell staining and caspase-3 activity (an enzyme involved in apoptosis).⁷ Whether these beta cell preservation effects translate into meaningfully slower disease progression in humans over many years remains an open question, but the preclinical signals are encouraging.

Not All DPP-4 Inhibitors Bind the Same Way

Five DPP-4 inhibitors are widely prescribed: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin. They all block the same enzyme, but they sit inside the enzyme’s active site differently, which matters for how tightly they bind and how selective they are. A structural comparison grouped them into three classes based on which pockets within the enzyme they occupy. Vildagliptin and saxagliptin form a covalent (permanent) bond with a key amino acid in the enzyme’s catalytic machinery, while alogliptin and linagliptin reach into additional subsites around the active site, and sitagliptin occupies yet another extended pocket.⁸

These binding differences feed into the clinically relevant differences between the drugs. They vary in half-life, how the body metabolizes and eliminates them, and how extensively they bind to blood proteins.⁹ One practical example: most DPP-4 inhibitors are cleared primarily through the kidneys, which means doses need to be adjusted for people with kidney disease. Linagliptin is the exception; it is eliminated mainly through the liver, so it can be prescribed at its standard dose even when kidney function is significantly reduced.¹⁰ For a patient whose kidneys are struggling, that distinction can drive the choice between one gliptin and another.

Why Selectivity for DPP-4 Over Related Enzymes Matters

DPP-4 belongs to a family of enzymes with similar structures. Two close relatives, DPP-8 and DPP-9, are found inside cells and play roles in immune function and cell survival. When early drug candidates accidentally inhibited DPP-8 and DPP-9 alongside DPP-4, the results in animals were ugly: hair loss, drops in blood cell counts, enlarged spleens, gut damage, and in rats, death.¹¹ A selective DPP-4-only inhibitor tested alongside produced none of those toxicities. That finding became a design principle for the entire drug class: to be safe, a DPP-4 inhibitor needs to leave DPP-8 and DPP-9 alone.

Achieving that selectivity comes down to exploiting small structural differences in the enzyme’s binding pockets. Research into the 3D shapes of DPP-4, DPP-8, and DPP-9 identified specific subsites where selective inhibitors can latch onto DPP-4 without fitting into the related enzymes.¹² All approved gliptins are highly selective for DPP-4, and this is a significant reason their safety profiles are as clean as they are. Newer compounds in development continue to push selectivity even further.¹³

The Cardiovascular Safety Story

After regulators began requiring cardiovascular safety trials for all new diabetes drugs, DPP-4 inhibitors went through a series of large outcome studies. The headline result across these trials was that the drugs did not raise the overall risk of major cardiovascular events like heart attacks and strokes.¹⁴ However, they did not reduce cardiovascular risk either, which set them apart from some newer drug classes that showed clear cardiovascular benefits.

The more complicated part of the story involves heart failure. The SAVOR-TIMI 53 trial found that saxagliptin increased hospitalizations for heart failure by about 27% compared with placebo. Alogliptin showed inconsistent signals across patient subgroups, while sitagliptin showed no effect on heart failure at all.¹⁵ The reasons behind this discrepancy between individual drugs remain debated. It may relate to differences in off-target effects, pharmacokinetics, or which patient populations were studied. For now, the practical takeaway is that cardiovascular safety is not identical across all gliptins, and clinicians pay closer attention when prescribing to patients who already have heart failure risk factors.

Effects Beyond Blood Sugar

Because DPP-4 has so many substrates beyond incretin hormones, blocking it has ripple effects that researchers have been cataloguing for years. Two areas with the most data are blood vessel health and kidney protection.

On the vascular side, animal studies consistently show that DPP-4 inhibitors increase nitric oxide availability and reduce oxidative stress, which improves the ability of blood vessels to relax. Some human studies have confirmed improved flow-mediated dilation (a standard measure of endothelial function) in patients with type 2 diabetes.¹⁶ But the picture is not all positive. Two independent trials of sitagliptin and alogliptin found that these drugs actually worsened endothelial function as measured by flow-mediated dilation, despite improving glycemic control.¹⁷ That seemingly contradictory finding has not been fully resolved, and it highlights how tricky it is to extrapolate from a drug’s mechanism to its real-world cardiovascular effects.

In the kidneys, both lab and clinical studies suggest DPP-4 inhibitors reduce inflammation, fibrosis, and oxidative damage in ways that go beyond simply lowering blood sugar.¹⁸ ¹⁹ These renoprotective signals are promising but have not translated into the kind of hard-endpoint kidney outcomes that SGLT2 inhibitors have demonstrated in large trials. DPP-4 inhibitors are often considered kidney-friendly for dosing purposes, especially linagliptin, but “kidney-friendly dosing” and “proven kidney protection” are different claims.

The Immune System Angle

DPP-4 has an alternate identity in immunology: it is the same molecule as CD26, a well-studied protein on the surface of T cells. CD26 plays a role in activating T cells, helping them communicate with other immune cells, and regulating immune responses. When T cells encounter something foreign, CD26 interacts with a protein called caveolin-1 on antigen-presenting cells, strengthening the connection between the two cells and boosting the immune response.²⁰

This dual life raises a reasonable question: does blocking DPP-4 with a diabetes drug affect immune function? In practice, the approved gliptins have not been linked to meaningful immunosuppression in clinical trials, and infection rates have generally been similar to placebo. There is a modest and somewhat inconsistent signal for slightly higher rates of upper respiratory infections and nasopharyngitis with some DPP-4 inhibitors, but the effect is small enough that it has not become a major clinical concern. Still, the immune connection means researchers keep an eye on long-term immune-related outcomes in DPP-4 inhibitor users, particularly as these drugs are sometimes prescribed for decades.

Combination With Other Diabetes Drugs

DPP-4 inhibitors are frequently prescribed alongside other glucose-lowering medications. One pairing that has gained traction is DPP-4 inhibitors with SGLT2 inhibitors, which work through an entirely separate mechanism (causing the kidneys to excrete more glucose in urine). The two drug classes lower blood sugar through complementary pathways, and fixed-dose combination pills have been approved to simplify treatment.²¹

A key concern with any drug combination is whether stacking glucose-lowering effects increases the risk of hypoglycemia. A meta-analysis of randomized trials found that the combination of an SGLT2 inhibitor and a DPP-4 inhibitor carried a similar hypoglycemia risk to either drug used alone.²² This makes sense mechanistically: both drug classes rely on glucose-dependent pathways, so neither pushes the system to release insulin when blood sugar is already normal. The pairing is particularly useful when a patient needs additional glucose lowering beyond what metformin alone provides but wants to avoid the weight gain or hypoglycemia risk that come with older drug classes like sulfonylureas.

Why Some People Respond Better Than Others

Not everyone gets the same benefit from DPP-4 inhibitors, and researchers have started looking at genetic variation to explain why. A genome-wide study in a Taiwanese population identified several gene variants linked to how well patients responded to DPP-4 inhibitors. The strongest signal was near a gene called PRKD1, which is involved in beta cell function and survival.²³ Other studies have flagged variants in the GLP-1 receptor gene itself (GLP1R) and in several other genes associated with beta cell biology and diabetes susceptibility as potential contributors to variable drug response.²⁴

One particularly counterintuitive finding came from a Japanese cohort, where people carrying risk alleles for type 2 diabetes in the CDKAL1 gene actually had a better response to DPP-4 inhibitors than those without the risk variants.²⁵ The running explanation is that the same genetic variation that impairs beta cell function may make those cells more reliant on incretin signaling, so amplifying that signal with a DPP-4 inhibitor produces a bigger improvement. None of these findings are ready for clinical use as genetic tests, but they hint at a future where drug selection could be tailored to a patient’s genetic profile.

Emerging Research on Brain Health

One of the more unexpected areas of DPP-4 inhibitor research involves the brain. Because GLP-1 receptors are expressed in the central nervous system and DPP-4 is active there, blocking the enzyme could theoretically increase neuroprotective signaling. Preclinical work has shown that DPP-4 inhibitors can reduce amyloid-beta plaque buildup, lower neuroinflammation, and protect against oxidative stress in brain tissue.²⁶ In one animal study, linagliptin improved cognitive performance in middle-aged mice, enhanced the formation of new neurons in the hippocampus, and shifted brain immune cells (microglia) toward a less inflammatory state.²⁷

Translating mouse brain studies to human Alzheimer’s prevention is a notoriously long and uncertain road. But the mechanistic rationale is interesting enough that epidemiological studies looking at whether DPP-4 inhibitor users develop dementia at different rates are underway. If you have heard about the excitement around GLP-1 receptor agonists and neurodegeneration, the DPP-4 inhibitor angle is a related but less advanced version of the same idea: keep more GLP-1 active in the brain, and you might slow some age-related damage. Whether the modest GLP-1 elevation from a DPP-4 inhibitor is enough to matter, compared with the pharmacological GLP-1 doses from injectable agonists, remains the central uncertainty.